Meeting
2014 ASCO Annual Meeting
A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors.
Authors
Dejan Juric
Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
Dejan Juric , Jean-Charles Soria , Sunil Sharma , Udai Banerji , Analia Azaro , Jayesh Desai , Francois Philippe Ringeisen , Audrey Kaag , Rajkumar Radhakrishnan , Florence Hourcade-Potelleret , Heiko Maacke , Jordi Rodon Ahnert
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Clinical Trial Registration Number
NCT01449058
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 9051)
DOI
10.1200/jco.2014.32.15_suppl.9051
Abstract #
9051
Poster Bd #
255
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors.
First Author: Hendrik-Tobias Arkenau
Poster
2021 ASCO Annual Meeting
Trial in progress: Phase 1a/b study of PF-07284890 (brain-penetrant BRAF inhibitor) with/without binimetinib in patients with BRAF V600-mutant solid tumors.
First Author: Vivek Subbiah
Poster
2020 ASCO Virtual Scientific Program
Phase I dose-finding study of oral ERK1/2 inhibitor LTT462 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.
First Author: Filip Janku
Poster
2017 Gastrointestinal Cancers Symposium
A phase I/II trial of MEK162 in combination with gemcitabine (G) and cisplatin (C) for patients (pts) with untreated advanced biliary cancer (ABC).
First Author: Maeve Aine Lowery